| NCT02075255 | AstraZeneca | Asthma | 2014-04-28 | PHASE3 |
| NCT03557307 | AstraZeneca | Asthma | 2018-08-01 | PHASE3 |
| NCT05552508 | AstraZeneca | Asthma | 2022-10-11 | PHASE4 |
| NCT02869438 | AstraZeneca | Asthma | 2016-11-09 | PHASE3 |
| NCT05692180 | AstraZeneca|Parexel | Asthma | 2023-04-05 | PHASE3 |
| NCT04552288 | Memorial Sloan Kettering Cancer Center | Solid Tumor|Solid Carcinoma|Solid Tumor, Adult|Hematologic Malignancy | 2020-09-16 | PHASE2 |
| NCT04098718 | University of Oxford | Asthma|COPD | 2021-03-29 | PHASE2 |
| NCT04305405 | AstraZeneca|IQVIA Pty Ltd|Parexel|Covance|PPD Development, LP | Severe Uncontrolled Asthma | 2019-11-21 | PHASE3 |
| NCT07214753 | AstraZeneca | Severe Eosinophilic Asthma | 2025-12-20 | |
| NCT03733535 | Dr. Grace Parraga|AstraZeneca | Asthma; Eosinophilic | 2022-03-01 | NA |
| NCT04617171 | Singapore General Hospital | Asthma Attack|Asthma | 2021-06-02 | PHASE2 |
| NCT06734884 | University Hospital, Lille|AstraZeneca | DRESS Syndrome | 2025-01-06 | PHASE2 |
| NCT03401229 | AstraZeneca | Nasal Polyposis | 2018-01-15 | PHASE3 |
| NCT01947946 | AstraZeneca | Asthma | 2013-11 | PHASE3 |
| NCT01238861 | MedImmune LLC|MedImmune Ltd | Asthma | 2010-12 | PHASE2 |
| NCT04053634 | AstraZeneca | Chronic Obstructive Pulmonary Disease | 2019-08-26 | PHASE3 |
| NCT02814643 | AstraZeneca | Asthma | 2016-07-01 | PHASE3 |
| NCT07444567 | AstraZeneca | Asthma|Eosinophilic Granulomatosis With Polyangiitis (EGPA)|Hypereosinophilic Syndrome (HES) | 2026-05-25 | PHASE3 |
| NCT03186209 | AstraZeneca | Asthma | 2017-09-07 | PHASE3 |
| NCT06465485 | AstraZeneca | Severe Eosinophilic Asthma | 2024-02-28 | PHASE3 |
| NCT01928771 | AstraZeneca | Asthma | 2013-09-19 | PHASE3 |
| NCT03953300 | AstraZeneca | Asthma | 2019-10-08 | PHASE4 |
| NCT00768079 | MedImmune LLC | Asthma | 2009-02-02 | PHASE2 |
| NCT03652376 | University of Rostock | Severe Eosinophilic Asthma | 2018-09-01 | PHASE4 |
| NCT04157348 | AstraZeneca | Eosinophilic Granulomatous Vasculitis | 2019-10-29 | PHASE3 |
| NCT02918071 | AstraZeneca | Asthma | 2016-11-10 | PHASE3 |
| NCT05384938 | AstraZeneca | In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India | 2021-11-19 | PHASE4 |
| NCT04605094 | AstraZeneca|IQVIA Pty Ltd | Atopic Dermatitis | 2020-11-12 | PHASE2 |
| NCT03183024 | Jonathan A. Bernstein, MD | Chronic Idiopathic Urticaria | 2017-09-12 | PHASE4 |
| NCT02968914 | AstraZeneca|Parexel | Asthma|Chronic Obstructive Pulmonary Disease | 2017-01-04 | PHASE1 |
| NCT05228041 | University Hospital, Lille | Chronic Rhinosinusitis With Nasal Polyps | 2022-02-10 | |
| NCT03473977 | Children´s Hospital Medical Center, Cincinnati|AstraZeneca | Eosinophilic Gastritis or Gastroenteritis | 2018-04-23 | PHASE2|PHASE3 |
| NCT02155660 | AstraZeneca|MedImmune LLC | Moderate to Very Severe Chronic Obstructive Pulmonary Disease | 2014-06-25 | PHASE3 |
| NCT03976310 | University Hospital, Montpellier|AstraZeneca | Asthma | 2019-06-20 | NA |
| NCT05006573 | AstraZeneca | Non-cystic Fibrosis Bronchiectasis | 2021-07-21 | PHASE3 |
| NCT04102800 | NHS Greater Glasgow and Clyde|University of Glasgow|AstraZeneca|Queen´s University, Belfast|Bosch Healthcare Solutions GmbH|InHealthcare|University of Leicester|University of Plymouth|Vitalograph | Asthma | 2019-09-30 | PHASE4 |
| NCT01227278 | MedImmune LLC|AstraZeneca | Pulmonary Disease, Chronic Obstructive | 2010-11 | PHASE2 |
| NCT06288516 | Aristotle University Of Thessaloniki|Pulmonary Clinic, University of Ioannina|Pulmonary Clinic, Democritus University of Thrace|2nd Pulmonary Clinic, Kapodistrian University of Athens|University Hospital of Crete|Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens|University Hospital of Patras | Asthma; Eosinophilic|Airway Remodeling | 2024-03-01 | PHASE4 |
| NCT05847452 | Guy´s and St Thomas´ NHS Foundation Trust|King´s College London | Asthma | 2023-05-22 | |
| NCT03450083 | Johns Hopkins University | Chronic Rhinosinusitis (Diagnosis)|Nasal Polyps|Eosinophilia | 2017-07-01 | PHASE2 |
| NCT02258542 | AstraZeneca | Asthma | 2014-11-19 | PHASE3 |
| NCT05966584 | Memorial Sloan Kettering Cancer Center|AstraZeneca|Novartis Pharmaceuticals | Breast Cancer | 2023-07-06 | PHASE2 |
| NCT00783289 | MedImmune LLC | Asthma | 2008-11-14 | PHASE2 |
| NCT06385236 | University of California, San Diego|Mayo Clinic|Yale University|University of Arizona|Harvard University|Brigham and Women´s Hospital|National Heart, Lung, and Blood Institute (NHLBI) | Moderate to Severe Asthma | 2024-02-19 | PHASE4 |
| NCT02808819 | AstraZeneca | Asthma | 2016-06-30 | PHASE3 |
| NCT06501807 | University Hospital, Lille | Rhinosinusitis Chronic|Nasal Polyps | 2024-09-02 | NA |
| NCT01914757 | AstraZeneca | Asthma | 2013-08 | PHASE3 |
| NCT05251909 | AstraZeneca | Eosinophilic Gastritis|Eosinophilic Gastroenteritis | 2022-01-18 | PHASE3 |
| NCT04185012 | Humanitas Clinical and Research Center|AstraZeneca | Nasal Polyps | 2020-02-24 | PHASE3 |
| NCT05932849 | AstraZeneca | Asthma | 2021-10-05 | |
| NCT02322775 | AstraZeneca | Asthma | 2015-02-02 | PHASE3 |
| NCT05180357 | AstraZeneca | Severe Eosinophilic Asthma|Nasal Polyps | 2021-11-23 | |
| NCT02130882 | National Institute of Allergy and Infectious Diseases (NIAID)|AstraZeneca | Respiratory System Agents|Anti-Asthmatic Agents|Hematologic Diseases|Leukocyte Disorders|Hypereosinophilia | 2014-05-19 | PHASE2|PHASE3 |
| NCT04612725 | AstraZeneca|IQVIA Pty Ltd | Chronic Spontaneous Urticaria | 2020-10-27 | PHASE2 |
| NCT02417961 | AstraZeneca | Asthma | 2015-04-27 | PHASE3 |
| NCT03563066 | McMaster University|AstraZeneca | Dermatitis, Atopic|Dermatitis|Eczema|Skin Diseases|Skin Diseases, Genetic|Genetic Diseases, Inborn|Skin Diseases, Eczematous|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases | 2018-09-04 | PHASE2 |
| NCT04612790 | AstraZeneca | Bullous Pemphigoid | 2021-03-31 | PHASE3 |
| NCT04191304 | AstraZeneca | Hypereosinophilic Syndrome | 2020-07-20 | PHASE3 |
| NCT03010436 | National Jewish Health|AstraZeneca | Asthma | 2017-04-15 | PHASE2 |
| NCT02821416 | AstraZeneca | Asthma | 2016-10-11 | PHASE3 |
| NCT04157335 | AstraZeneca | Nasal Polyposis|Eosinophilic Chronic Rhinosinusitis | 2019-11-25 | PHASE3 |
| NCT06750289 | AstraZeneca | Eosinophilic Asthma | 2025-03-28 | PHASE3 |
| NCT04565483 | Nantes University Hospital|AstraZeneca|Ministère de la Santé - France | Asthma; Eosinophilic|Severe Asthma | 2021-10-11 | PHASE4 |
| NCT05273359 | Temple University|AstraZeneca | Chronic Obstructive Pulmonary Disease (COPD) | 2023-04 | PHASE2 |
| NCT03470311 | McMaster University|St. Joseph´s Healthcare Hamilton|AstraZeneca | Severe Prednisone Dependent Eosinophilic Asthma | 2018-04-26 | PHASE3 |
| NCT06512883 | AstraZeneca | Eosinophilic Granulomatosis With Polyangiitis (EGPA)|Hypereosinophilia Syndrome (HES) | 2025-04-17 | PHASE3 |
| NCT04742504 | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Asthma; Eosinophilic | 2021-09-07 | |
| NCT03928262 | AstraZeneca | Healthy Subjects | 2019-04-02 | PHASE1 |
| NCT04718389 | GlaxoSmithKline|IQVIA Pty Ltd | Asthma | 2021-01-26 | PHASE3 |
| NCT04665141 | Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinic of Barcelona|Hospital Regional de Malaga | Asthma | 2021-04-07 | |
| NCT03327701 | Louis-Philippe Boulet|AstraZeneca | Asthma, Exercise-Induced | 2017-12 | PHASE3 |
| NCT03170271 | AstraZeneca | Asthma | 2017-07-07 | PHASE3 |
| NCT04543409 | AstraZeneca | Eosinophilic Esophagitis | 2020-09-22 | PHASE3 |
| NCT00659659 | MedImmune LLC | Asthma | 2008-01 | PHASE1 |
| NCT00512486 | MedImmune LLC | Asthma | 2006-11 | PHASE1 |
| NCT01412736 | Kyowa Kirin Co., Ltd. | Uncontrolled and Suspected Eosinophilic Asthma | 2011-08 | PHASE2 |